Functional connectivity increase in the default-mode network of patients with Alzheimer's disease after long-term treatment with Galantamine
- PMID: 26796681
- DOI: 10.1016/j.euroneuro.2015.12.006
Functional connectivity increase in the default-mode network of patients with Alzheimer's disease after long-term treatment with Galantamine
Abstract
Acetylcholinesterase inhibitors (AChEIs) are efficacious for the treatment of mild to moderate forms of Alzheimer's dementia (AD). Default-mode network (DMN) connectivity is considered to be early impaired in AD. Long-term effects of AChEIs on the DMN in AD have not yet been investigated. Twenty-eight AD patients and 11 age-matched healthy volunteers (HC) participated in the prospective study. AD patients were randomly assigned to either a pharmacotherapy arm (Galantamine, AD G) or to a placebo arm (AD P+G) for the period of 6 months followed by open-label Galantamine therapy from month 7-12. All subjects underwent neuropsychological testing, resting-state functional and structural MRI at baseline and after 12 months, AD patients additionally in between after 6 months. Thirteen AD patients completed the treatment trial and underwent all functional MRI follow-up sequences of good quality. Functional connectivity significantly increased within the AD G group in the posterior cingulate cortex and in the Precuneus between baseline and 12 months follow-up (pcorr<0.05). Between-group analyses demonstrated that functional connectivity in the AD G group significantly increased in the posterior cingulate cortex as well as in the Precuneus compared to the HC group and in the anteromedial aspect of the temporal lobes compared to the AD P+G group, respectively, at 12 months follow-up (pcorr<0.05). Cognitive performance remained stable within groups over time indicating that resting-state fMRI may be sensitive for the detection of pharmacologically induced effects on brain function of AD patients.
Trial registration: ClinicalTrials.gov NCT00523666.
Keywords: Alzheimer׳s disease; Default-mode network; Galantamine; Resting-state functional connectivity; Voxel-based morphometry.
Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved.
Similar articles
-
Distinctive Resting State Network Disruptions Among Alzheimer's Disease, Subcortical Vascular Dementia, and Mixed Dementia Patients.J Alzheimers Dis. 2016;50(3):709-18. doi: 10.3233/JAD-150637. J Alzheimers Dis. 2016. PMID: 26757039
-
Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease.Neuroimage. 2019 Oct 1;199:143-152. doi: 10.1016/j.neuroimage.2019.05.044. Epub 2019 May 18. Neuroimage. 2019. PMID: 31112788 Clinical Trial.
-
A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease.J Alzheimers Dis. 2017;55(2):521-537. doi: 10.3233/JAD-150695. J Alzheimers Dis. 2017. PMID: 27662284
-
Update on Alzheimer drugs (galantamine).Neurologist. 2003 Sep;9(5):235-40. doi: 10.1097/01.nrl.0000087722.46430.c4. Neurologist. 2003. PMID: 12971834 Review.
-
Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.CNS Drug Rev. 2002 Summer;8(2):159-76. doi: 10.1111/j.1527-3458.2002.tb00221.x. CNS Drug Rev. 2002. PMID: 12177686 Free PMC article. Review.
Cited by
-
Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review.Alzheimers Res Ther. 2018 Feb 20;10(1):21. doi: 10.1186/s13195-018-0347-1. Alzheimers Res Ther. 2018. PMID: 29458420 Free PMC article. Review.
-
Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD001747. doi: 10.1002/14651858.CD001747.pub4. Cochrane Database Syst Rev. 2024. PMID: 39498781
-
ABCA7 polymorphisms correlate with memory impairment and default mode network in patients with APOEε4-associated Alzheimer's disease.Alzheimers Res Ther. 2019 Dec 12;11(1):103. doi: 10.1186/s13195-019-0563-3. Alzheimers Res Ther. 2019. PMID: 31831047 Free PMC article.
-
Ameliorating Alzheimer's-like Pathology by Minocycline via Inhibiting Cdk5/p25 Signaling.Curr Neuropharmacol. 2022 Aug 3;20(9):1783-1792. doi: 10.2174/1570159X19666211202124925. Curr Neuropharmacol. 2022. PMID: 34856907 Free PMC article.
-
Neural Correlates of Sleep Disturbance in Alzheimer's Disease: Role of the Precuneus in Sleep Disturbance.J Alzheimers Dis. 2018;63(3):957-964. doi: 10.3233/JAD-171169. J Alzheimers Dis. 2018. PMID: 29710710 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical